Navigation Links
Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
Date:1/3/2012

WORCESTER, Mass. and TORONTO, Jan. 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.  Positive interim Phase 2b clinical data from the study in HER-2 expressing breast cancer subjects (presented last month at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas) has lead to an earlier-than-expected advancement in the overall development of AE37 for both breast and prostate cancer indications.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

AE37 is a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine designed to train the immune system, independent of HLA-type, to track down cancer cells throughout the body and destroy them.  The positive interim Phase 2b results, building upon completed pre-clinical and Phase I breast cancer studies, enables Antigen Express to move up the timing of key development and regulatory plans.  In particular, the company will organize an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) by the end of Q1 2012.  With the FDA's guidance, the Company will move into a pivotal Phase 3 clinical development program in women with loco-regional breast cancer that express low to moderate levels of HER2.  Parallel steps will be taken with the European Medicines Agency using the same Phase 2b results.  The Phase 2b is currently planned to enroll a total of 300 women and will continue as planned to provide additional valuable information on efficacy and safety of AE37 as the Company pursues its Phase 3 trial plans.

Dr. Eric von Hofe, Ph.D., President of Antigen Express, said: "While the number of patients with recurrent breast cancer is still too low to confirm statistical significance in this ongoing study, the approximate
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
4. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
5. Generex Provides Update on Spinout of Antigen Express
6. Generex Augments Cash Position With Sales of Non-Essential Assets
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
9. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
10. Generex Provides Clarification of Facts
11. Generex Announces Results of Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... MDV-Mohr Davidow Ventures, a,leading Silicon Valley venture capital ... Dan Riskin to the firm as Executive-in-Residence and,Entrepreneur-in-Residence, ... provide healthcare providers and consumers more effective,ways to ... diagnosis to the,treatment of disease. , ...
... Switzerland and BANGALORE, India, November 20 ... development,specialist that focuses on serious medical ... Technologies Ltd (Aurigene), a,Bangalore-based fully integrated, ... peptide drug discovery and development from ...
... Nov. 19 Serica Technologies, Inc., a,growth-stage ... tissue regeneration, today announced that it has ... standards,required for medical device manufacturers. ISO certification ... regulatory bodies worldwide as proof of an,effective ...
Cached Biology Technology:MDV Expands Team Pursuing Advances in Personalized Medicine 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 3Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 2Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 3Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 4
(Date:4/15/2014)... at UC San Diego have succeeded in visualizing ... responsible for growth and resistance to drought. The ... to determine how the hormone helps plants respond ... the continuing increase in the atmosphere,s carbon dioxide, ... appears in the April 15 issue of the ...
(Date:4/15/2014)... New Zealand,s pastoral landscapes are some of the loveliest ... threat. Many of the country,s pasture soils have become ... metal, which is then eaten by the cattle and ... to New Zealand; cadmium-enriched soils being reported worldwide. , ... unsafe levels in meat and dairy products, human health ...
(Date:4/15/2014)... 2050, deforestation could cause temperatures in the Congo ... would intensify warming caused by greenhouse gases by ... the University of Leuven, Belgium. , Explosive population ... destruction of tropical rainforests in Central Africa. A ... examined how these practices will affect longer-term temperatures ...
Breaking Biology News(10 mins):Biologists develop nanosensors to visualize movements and distribution of plant hormone 2Study: Deforestation could intensify climate change in Congo Basin by half 2
... 2011) Researchers looking to find a root cause for ... a novel investigative approach that borders on science fiction as ... the nation,s No. 1 killer. The National Institutes of ... Scripps Translational Science Institute (STSI) of San Diego and Sangamo ...
... wide variety of new cut flower cultivars and species ... University and the Association of Specialty Cut Flower Growers. ... United States and Canada, provides valuable production and marketing ... team from North Carolina State University undertook a multiyear ...
... Stephane Len, both researchers at the IRMES (Institut de ... France), have published their findings in Age , ... the evolution of performances in elite athletes and chess ... developed by the laboratory, and suggests that changes in ...
Cached Biology News:Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack 2Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack 3Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack 4Extending the vase life of cut flowers: Pre-treatments and preservatives studied 2Evolution of sport performances follows a physiological law 2
... able to handle larger sample volumes, automate infusions, ... interface with telemetry systems. The AccuSampler LA ... pigs, and primates. The system may be ... computer can be located outside the animal room ...
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... key to successful cell culture or fermentation ... during the process, and make rapid adjustments ... Nova BioProfile Chemistry Analyzers provide immediate analysis ... cell culture and fermentation media. BioProfile analyzers ...
... AAIPharmas Routine Testing Laboratory (RTL) ... developed over 25 years. ,,Microbial method ... used to monitor the conditions of ... quality for manufactured products,,We offer a ...
Biology Products: